Advertisement

Waiting list trends for liver transplantation in Italy: A snapshot from the future

  • Alessio Aghemo
    Affiliations
    Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy

    Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
    Search for articles by this author
  • Quirino Lai
    Correspondence
    Corresponding author at: General Surgery and Organ Transplantation Unit, Department of General and Specialistic Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
    Affiliations
    General Surgery and Organ Transplantation Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Italy
    Search for articles by this author
Published:October 12, 2022DOI:https://doi.org/10.1016/j.dld.2022.09.013
      In recent years, significant changes have been observed in the field of liver transplantation (LT). On one side, the introduction of direct-acting antivirals (DAA) has modified the impact of HCV, mainly in areas like Italy, where the virus was endemic [
      • Menini F.S.
      • Marcellusi A.
      • Robbins Scott S.
      • et al.
      The impact of direct acting antiviral on Hepatitis C virus disease burden and associated cots in four European countries.
      ]. On the other side, a growing number of patients with metabolic dysfunction-associated fatty liver disease (MAFLD) has been reported, mainly in countries with a high prevalence of obesity [
      • Cholankeril G.
      • Wong R.J.
      • Hu M.
      • et al.
      Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes.
      ]. Nevertheless, Italy is also experiencing an increase in this pathology [
      • Vitale A.
      • Svegliati-Baroni G.
      • Ortolani A.
      • et al.
      Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Menini F.S.
        • Marcellusi A.
        • Robbins Scott S.
        • et al.
        The impact of direct acting antiviral on Hepatitis C virus disease burden and associated cots in four European countries.
        Liver Int. 2021; 41: 934-948
        • Cholankeril G.
        • Wong R.J.
        • Hu M.
        • et al.
        Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes.
        Dig Dis Sci. 2017; 62: 2915-2922
        • Vitale A.
        • Svegliati-Baroni G.
        • Ortolani A.
        • et al.
        Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
        Gut. 2021 Dec 21; (gutjnl-2021-324915)
        • Younossi Z.
        • Stepanova M.
        • Ong J.P.
        • et al.
        Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.
        Clin Gastroenterol Hepatol. 2019; 17 (.e3): 748-755
        • Sapisochin G.
        • Hibi T.
        • Toso C.
        • et al.
        Transplant oncology in primary and metastatic liver tumors: principles, evidence, and opportunities.
        Ann Surg. 2021; 273: 483-493
        • Manzia T.M.
        • Trapani S.
        • Nardi A.
        • et al.
        Temporal trends of waitlistings for liver transplantation in Italy: the ECALITA (Evolution of IndiCAtion in LIver Transplantation in ITAly) Registry Study.
        Dig Liver Dis. 2022; 54: 1664-1671
        • Belli L.S.
        • Berenguer M.
        • Cortesi P.A.
        • et al.
        Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study.
        J Hepatol. 2016; 65: 524-531
        • Arora S.S.
        • Axley P.
        • Ahmed Z.
        • Satapathy S.K.
        • Wong R.
        • Kuo Y.F.
        • Singal A.K.
        Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
        Transpl Int. 2019; 32: 854-864
        • Fei Ye F.
        • Zhai M.
        • Long J.
        • et al.
        The burden of liver cirrhosis in mortality: results from the global burden of disease study.
        Front Public Health. 2022; 10909455
        • Park C.W.
        • Tsai N.T.
        • Wong L.L.
        Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more.
        Clin Transplant. 2011; 25: E606-E611
        • Yang J.D.
        • Larson J.J.
        • Watt K.D.
        • Allen A.M.
        • Wiesner R.H.
        • Gores G.J.
        • Roberts L.R.
        • Heimbach J.A.
        • Leise M.D.
        Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States.
        Clin Gastroenterol Hepatol. 2017; 15 (.e3): 767-775
        • Guarino M.
        • Viganò L.
        • Ponziani F.R.
        • et al.
        Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: literature review and risk analysis.
        Dig Liver Dis. 2018; 50: 1105-1114
        • Lerut J.
        • Foguenne M.
        • Lai Q.
        Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score.
        Updates Surg. 2021; 73: 1599-1614
        • Solheim J.M.
        • Dueland S.
        • Line P.D.
        • Hagness M.
        Transplantation for nonresectable colorectal liver metastases - long term follow- up of the first prospective pilot study.
        Ann Surg. 2022 Sep 9; https://doi.org/10.1097/SLA.0000000000005703
        • Ravaioli M.
        • Lai Q.
        • Sessa M.
        • et al.
        Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
        J Hepatol. 2022; 76: 619-627

      Linked Article